Reliability note

Titles and AI summaries are unofficial English monitoring aids, not legal advice or official translations. Each link opens the original Japanese official source, which remains authoritative.

PMDA announcement: caution against confusing Fungizone and AmBisome

「製薬企業からの医薬品の安全使用に関するお知らせ」に「ファンギゾンとアムビゾームの取り違え注意のお願い」を掲載しました

Published: 2026-10-30 · Source: Pharmaceuticals and Medical Devices Agency (PMDA) — Safety Updates · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Low · First detected by this dashboard: 2026-10-31

View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard

AI summary

Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.

Summary

On 2026-10-30, the Pharmaceuticals and Medical Devices Agency (PMDA) announced that it had posted a notice cautioning against confusing Fungizone and AmBisome. The notice was listed under pharmaceutical companies' information on the safe use of medicines.

Business Impact

Healthcare professionals handling Fungizone and AmBisome may find the notice relevant to avoiding mix-ups between these medicines.

Recommended Action

Review of the official Japanese notice would help clarify the products concerned and the specific precautions against mix-ups.